Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Altergon S.A. is currently active in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 3 pending office actions. These matters are handled by a matching count of distinct examiners, ensuring that the workload is spread across different individuals. The prosecution occurs within 3 distinct art units, which points to a range of technical specializations for the company's filings.
The busiest examiner is LIU, TRACY, who is assigned 1 busiest examiner pending office action. Because the total number of pending office actions is the same as the count of distinct examiners, each examiner is responsible for a unique case. The 1 busiest examiner pending action represents the maximum load for any individual examiner in this set. The Biotechnology & Pharmaceuticals classification suggests the applications involve complex life sciences subject matter.
Practitioners should note that the different art units may have different allowance rates and procedural norms. The examiners will each bring a unique perspective to the pending office actions. Managing the different art units requires a flexible approach to patent prosecution. The role of LIU, TRACY is limited to the current pending matter at this time.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, TRACY | 1 | 54.5% | +27.3% |
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757455 | SYNOVIAL FLUID SUBSTITUTES | MACH, ANDRE | 7d |
| 18254864 | SOLUBLE POLYELECTROLYITIC COMPLEXES OF POLYMERIC BIGUANIDINE MICROBIOCIDES WITH GLYCOSAMINOGLYCANS | LIU, TRACY | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757455 | SYNOVIAL FLUID SUBSTITUTES | MACH, ANDRE | 7d |
| 18254864 | SOLUBLE POLYELECTROLYITIC COMPLEXES OF POLYMERIC BIGUANIDINE MICROBIOCIDES WITH GLYCOSAMINOGLYCANS | LIU, TRACY | 41d |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1693 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18254864 | SOLUBLE POLYELECTROLYITIC COMPLEXES OF POLYMERIC BIGUANIDINE MICROBIOCIDES WITH GLYCOSAMINOGLYCANS | LIU, TRACY | 1614 | §103§112 | Final Rejection | 41d | Pending | May 29, 2023 |
| 17757453 | INJECTABLE MIXTURES OF HYALURONIC ACID FOR USE IN DERMO-AESTHETICS | KRISHNAN, GANAPATHY | 1693 | §103DP | Final Rejection | 17d overdue | Pending | Jun 16, 2022 |
| 17757455 | SYNOVIAL FLUID SUBSTITUTES | MACH, ANDRE | 1615 | §102§103 | Final Rejection | 7d | Pending | Jun 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial